bgt007
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 30, 2022 (NCT05616468)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06478225 | N/A | May 7, 2024 | Jiao Tong University |
| NCT06104215 | Early Phase 1 (Phase 1) | Oct 22, 2023 | Government of China, Xuzhou Medical University |
| NCT06104241 | Early Phase 1 (Phase 1) | Oct 22, 2023 | Government of China, Xuzhou Medical University |
| NCT05616468 | Early Phase 1 (Phase 1) | Dec 30, 2022 | Government of China, Xuzhou Medical University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 0 | 1 | 2022 |
| Xuzhou Medical University | Academic/Hospital | 3 | 3 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1